AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28934837
Drug: 1W bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1W bromocriptine treatment (2.5 mg for 7 days)
Trial: 28934837
Drug: 8W bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8W bromocriptine treatment (5 mg for 2 weeks followed by 2.5 mg for 6 weeks)
Trial: 28934837
Drug: 1W bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1W bromocriptine treatment
Trial: 28934837
Drug: 8W bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8W bromocriptine treatment
Trial: 25238025
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (RE) 100, 250, 500 or 1000 mg once daily or 250 mg twice daily
Trial: 25238025
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone once daily
Trial: 20878572
Drug: Paclitaxel combined
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle
Trial: 20878572
Drug: Paclitaxel combined
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy
Trial: 20878572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received surgery within 2 weeks and postoperative chemotherapy of 6 cycles of paclitaxel combined with FOLFOX4 regimen
Trial: 12802023
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly injections
Trial: 12802023
Drug: Placebo (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inert oil) weekly injections
Trial: 1891485
Drug: Alprazolam (1.48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1.48 mg daily)
Trial: 1891485
Drug: Oxazepam (44.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (44.4 mg daily)
Trial: 6576616
Drug: Short-term psychotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychotherapy (one-hour weekly sessions for a maximum of ten sessions)
Trial: 6576616
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (control group)
Trial: 30198775
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron isomaltoside (IVI)
Trial: 22923433
Drug: Everolimus (mTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (mTOR inhibitor)
Trial: 8988412
Drug: Azithromycin (AZM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (AZM), 100 mg capsules or 10% fine granules, given orally
Trial: 8988412
Drug: Azithromycin (AZM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (AZM), 8.3 mg/kg once daily for 3 days
Trial: 8988412
Drug: Azithromycin (AZM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (AZM), 12.5 mg/kg once daily for 3 days
Trial: 1617930
Drug: roxithromycin (ROX)
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (ROX) 150 mg b.i.d. orally (n = 244)
Trial: 1617930
Drug: amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin plus clavulanic acid (AMX + CA) 500 mg AMX + 125 mg CA t.i.d. orally (n = 246)
Trial: 1617930
Drug: amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxicillin plus clavulanic acid (AMX + CA)
Trial: 6398125
Drug: Fosfomycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin plus amoxicillin (CFL)
Trial: 30084900
Drug: Silicone cream
RxNorm normalized name: REMEDY SILICONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone cream
Trial: 26308179
Drug: Carn‐BA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carn‐BA (2 g of L‐carnosine and 2 g of β‐alanine)
Trial: 12829905
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis for spontaneous bacterial peritonitis
Trial: 12829905
Drug: Prior antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior antifungal prophylaxis
Trial: 11214766
Drug: tiopronin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiopronin (200 mg/day) for 14 days
Trial: 11214766
Drug: tiopronin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiopronin (500 mg/day) for 14 days
Trial: 11214766
Drug: bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromocriptine (5 mg/day) for 14 days
Trial: 11214766
Drug: conservative measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conservative measures (no medication)
Trial: 11214766
Drug: tiopronin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiopronin (200 mg/day)
Trial: 11214766
Drug: tiopronin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiopronin (500 mg/day)
Trial: 11214766
Drug: bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bromocriptine (5 mg/day)
Trial: 11214766
Drug: tiopronin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiopronin (200 mg/day) and bromocriptine
Trial: 1670746
Drug: Doxazosin (11.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (11.9 +/- 0.9 mg daily)
Trial: 30698554
Drug: Recognan (citicoline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recognan (citicoline) 500 mg (5 ml) orally for 30 days
Trial: 26690861
Drug: Electronic Personal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic Personal Administration of Cognitive Therapy (ePACT)
Trial: 22424000
Drug: Intravenous glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose, insulin, and potassium (GIK) administered prehospital by paramedics
Trial: 22424000
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered prehospital by paramedics
Trial: 11873008
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg), one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Trial: 11873008
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Trial: 11873008
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg) among women with CD4 cell counts < 500/ml
Trial: 11873008
Drug: Placebo among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo among women with CD4 cell counts < 500/ml
Trial: 11873008
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg) among women with CD4 cell counts >= 500/ml
Trial: 11873008
Drug: Placebo among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo among women with CD4 cell counts >= 500/ml
Trial: 9864079
Drug: Buspirone (20‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (20‐30 mg/day) added to selective serotonin reuptake inhibitors (SSRIs)
Trial: 9864079
Drug: Buspirone (20‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (20‐30 mg/day) added to clomipramine
Trial: 9864079
Drug: Buspirone augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone augmentation therapy
Trial: 8680900
Drug: 1.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/day mesalazine
Trial: 8680900
Drug: 3.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/day mesalazine
Trial: 2220604
Drug: Enalapril (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (daily doses ranged from 2.5 to 40 mg)
Trial: 477676
Drug: Levamisole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Trial: 477676
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Trial: 21827664
Drug: Black sesame
RxNorm normalized name: ROSEMARY OIL 5 g in 100 g TOPICAL CREAM [GZE Black Sesame Rosemary Keratin HairMask]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black sesame meal (2.52 g capsules daily for 4 weeks)
Trial: 21827664
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (daily for 4 weeks)
Trial: 9782219
Drug: Short-term prophylaxis
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 15 days)
Trial: 9782219
Drug: Long-term prophylaxis
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 30 days)
Trial: 3410606
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg i.v. methylepoxyproscillaridin (P35)
Trial: 3410606
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral methylepoxyproscillaridin (P35)
Trial: 30630108
Drug: Monthly newsletter
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly newsletter (control)
Trial: 28727701
Drug: Blinded placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded placebo shockwave treatment
Trial: 28727701
Drug: Unblinded placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unblinded placebo shockwave treatment
Trial: 23153437
Drug: PlyD1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PlyD1 at 10 μg
Trial: 23153437
Drug: PlyD1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PlyD1 at 25 μg
Trial: 23153437
Drug: PlyD1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PlyD1 at 50 μg
Trial: 16488376
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg glatiramer acetate
Trial: 16488376
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glatiramer acetate
Trial: 29750366
Drug: Choline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplementation (2 g daily oral dose)
Trial: 27358385
Drug: Palonosetron (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.75 mg)
Trial: 10737366
Drug: Preoperative pentoxifiline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative pentoxifiline (PTFL) administration
Trial: 9189781
Drug: Flavored, 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored, 6% sucrose drink containing 25 mmol/L NaCl (LNa(+)‐R)
Trial: 9189781
Drug: Flavored, 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored, 6% sucrose drink containing 50 mmol/L NaCl (HNa(+)‐R)
Trial: 3872836
Drug: Carprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carprofen (300 mg/day)
Trial: 29150850
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg/d)
Trial: 29150850
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 mg/d)
Trial: 20097780
Drug: Collaborative depression
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative depression care (problem-solving therapy and/or antidepressant medication, telephone follow-up, systems navigation assistance)
Trial: 12576246
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of mifepristone
Trial: 12576246
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of mifepristone
Trial: 10382880
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 400 mg moxifloxacin
Trial: 10382880
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 400 mg moxifloxacin
Trial: 21816681
Drug: 2-year multilevel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-year multilevel intervention with monthly on-site consultation from expert nurses
Trial: 21816681
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control with monthly information about aging and physical assessment of elders
Trial: 17919894
Drug: Pioglitazone (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-30 mg/day) added to metformin or sulphonylurea
Trial: 17919894
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of metformin (400mg) and glibenclamide (2.5 mg)
Trial: 12809818
Drug: Medical (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical (ranitidine 150 mg t.i.d.)
Trial: 12809818
Drug: Control (antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antacids as needed)
Trial: 3926614
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide dinitrate in sustained-release form (sustained-release ISDN)
Trial: 3926614
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide 5-mononitrate (IS 5-MN)
Trial: 3926614
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg buccal nitroglycerin in sustained-release form (NTGB)
Trial: 3926614
Drug: 6.5 mg
RxNorm normalized name: menthol 6.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg oral nitroglycerin in sustained-release form (NTGO)
Trial: 29636305
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (5% of MIP) for 6 weeks
Trial: 27821107
Drug: Electro-acupuncture treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture treatments
Trial: 22480187
Drug: Moderate insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate insulin therapy (MIT) with glucose target 120 to 140 mg/dl
Trial: 22480187
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (CIT) with glucose target 180 to 200 mg/dl
Trial: 20678878
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day plus ASA 75 to 100 mg/day
Trial: 20678878
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ASA 75 to 100 mg/day
Trial: 8777101
Drug: Diltiazem 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 0.2 mg kg‐1
Trial: 8777101
Drug: Verapamil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 0.1 mg kg‐1
Trial: 2051002
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate 400 mg per day
Trial: 6881428
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solutions (ORS) containing 90 mmol/liter of sodium
Trial: 6881428
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solutions (ORS) containing 50 mmol/liter of sodium
Trial: 30075736
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m2 weekly for five courses
Trial: 30075736
Drug: Two to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two to four cycles of TP (Taxol 135 mg/m2, D1, and DDP 75 mg/m2, D1‐3) sequential chemotherapy
Trial: 24904748
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy combined with spinal manipulation
Trial: 18480682
Drug: Peony‐Glycyrrhiza Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peony‐Glycyrrhiza Decoction (PGD) 45 g/d
Trial: 18480682
Drug: Bromocriptine (BMT)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BMT) 5 mg/d
Trial: 16316784
Drug: Pulse steroid
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse steroid therapy
Trial: 16316784
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose steroid treatment
Trial: 14627912
Drug: Steroid-free protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free protocol with modified dosing
Trial: 14627912
Drug: Historical matched
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical matched steroid-based control
Trial: 10998732
Drug: Pharmacologic treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment, radiotherapy, and radioisotopes
Trial: 8795448
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (30 p.p.m. for 15 min)
Trial: 8795448
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (80 p.p.m. for 15 min)
Trial: 8795448
Drug: Prolonged inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged inhalation of nitric oxide (30 p.p.m. for 55 min)
Trial: 8795448
Drug: Aspirin (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (640 mg orally)
Trial: 30554365
Drug: Glycerine iodine
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerine iodine 10% daily for 7 days
Trial: 30554365
Drug: Neem seeds
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neem seeds extract (20% cream) daily for 10 days
Trial: 30554365
Drug: Sumaq extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumaq extract (5% cream) daily for 10 days
Trial: 28301614
Drug: HP lotion
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP lotion (halobetasol propionate 0.01%)
Trial: 25297660
Drug: Patient-led titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-led titration
Trial: 25297660
Drug: Physician-led titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-led titration
Trial: 18654783
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Gd-DTPA (approximately 0.1 mmol/kg bw)
Trial: 18654783
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of Gd-DTPA
Trial: 17032158
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy plus treatment as usual (CBT plus TAU)
Trial: 12937052
Drug: Dexamethasone administration
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administration (1993-1994 cohort)
Trial: 12937052
Drug: Dexamethasone administration
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administration (2001 cohort)
Trial: 10664926
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution (0.5%, 0.05 mL to each eye) with cimetidine (400 mg)
Trial: 10664926
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution (0.5%, 0.05 mL to each eye)
Trial: 8981292
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 50 mg daily
Trial: 8981292
Drug: Modified-release dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release dipyridamole 400 mg daily
Trial: 9287258
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASA 25 mg b.d. and dipyridamole 200 mg b.d.
Trial: 8345978
Drug: Oral amoxicillin/potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/potassium clavulanate
Trial: 3013567
Drug: Parenteral sulbactam/ampicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral sulbactam/ampicillin